PMC:7170415 / 22876-23732
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T42 | 7-11 | Body_part | denotes | face | http://purl.org/sig/ont/fma/fma24728 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T22 | 7-11 | Body_part | denotes | face | http://purl.obolibrary.org/obo/UBERON_0001456 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T209 | 7-11 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | face |
| T210 | 15-16 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T211 | 74-81 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T212 | 348-353 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T213 | 635-646 | http://purl.obolibrary.org/obo/OBI_0000968 | denotes | instruments |
| T214 | 658-661 | http://purl.obolibrary.org/obo/CL_0000990 | denotes | CDC |
| T215 | 693-695 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
| T216 | 755-759 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
| T217 | 837-841 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T35 | 378-386 | Chemical | denotes | reagents | http://purl.obolibrary.org/obo/CHEBI_33893 |
| T36 | 585-597 | Chemical | denotes | nucleic acid | http://purl.obolibrary.org/obo/CHEBI_33696 |
| T37 | 593-597 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T161 | 0-164 | Sentence | denotes | In the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. |
| T162 | 165-392 | Sentence | denotes | Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). |
| T163 | 393-562 | Sentence | denotes | University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. |
| T164 | 563-697 | Sentence | denotes | Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). |
| T165 | 698-856 | Sentence | denotes | National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers. |